Is Beam Therapeutics Inc. (BEAM) One of the Best Genomics Stocks to Buy According to Analysts?

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 8 Best Genomics Stocks to Buy According to Analysts.

On May 18, 2026, Beam Therapeutics Inc. (NASDAQ:BEAM) presented updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency at the American Thoracic Society International Conference. The firm detailed safety, durability, and reduced neutrophil elastase activity following treatment. It stated the data were made on topline results from 29 patients treated as of a February 10 cutoff, with extra insights from single-dose cohorts.

Is Beam Therapeutics Inc. (BEAM) One of the Best Genomics Stocks to Buy According to Analysts?

Chief Medical Officer Amy Simon said the findings support treating AATD “at the root cause of disease” using a one-time gene-editing therapy. Amy noted that Beam Therapeutics Inc. (NASDAQ:BEAM) is advancing toward pivotal development. Separately, trial investigator John Hurst said the results suggest a single dose can restore AAT function, calling the approach “a paradigm shift.”

The company said it plans to pursue quick approval following FDA feedback, expecting to enroll about 50 more patients and start a pivotal cohort in the second half of 2026.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology firm. It is involved in the establishment of an integrated platform for precision genetic medicines.

While we acknowledge the risk and potential of BEAM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BEAM and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1